Evidence map›Paper›PMID 27226562›Full record

ArticleThe Journal of biological chemistry2016

Systems-wide Experimental and Modeling Analysis of Insulin Signaling through Forkhead Box Protein O1 (FOXO1) in Human Adipocytes, Normally and in Type 2 Diabetes.

Meenu Rohini Rajan, Elin Nyman, Preben Kjølhede, Gunnar Cedersund, Peter Strålfors

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Finding new edges: systems approaches to MTOR signaling.Biochemical Society transactions · 2021
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Meenu Rohini RajanFrom the Departments of Clinical and Experimental Medicine and.
Elin NymanBiomedical Engineering, Linköping University, SE58185 Linköping, Sweden and Cardiovascular and Metabolic Diseases, Innovative Medicines, and Drug Metabolism and Pharmacokinetics, AstraZeneca Research and Development, 43150 Gothenburg, Sweden.
Preben KjølhedeFrom the Departments of Clinical and Experimental Medicine and.
Gunnar CedersundFrom the Departments of Clinical and Experimental Medicine and Biomedical Engineering, Linköping University, SE58185 Linköping, Sweden and.
Peter StrålforsFrom the Departments of Clinical and Experimental Medicine and peter.stralfors@liu.se.ORCID 0000-0002-1196-1806
Linköping University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin resistance is a major aspect of type 2 diabetes (T2D), which results from impaired insulin signaling in target cells. Signaling to regulate forkhead box protein O1 (FOXO1) may be the most important mechanism for insulin to control transcription. Despite this, little is known about how insulin regulates FOXO1 and how FOXO1 may contribute to insulin resistance in adipocytes, which are the most critical cell type in the development of insulin resistance. We report a detailed mechanistic analysis of insulin control of FOXO1 in human adipocytes obtained from non-diabetic subjects and from patients with T2D. We show that FOXO1 is mainly phosphorylated through mTORC2-mediated phosphorylation of protein kinase B at Ser(473) and that this mechanism is unperturbed in T2D. We also demonstrate a cross-talk from the MAPK branch of insulin signaling to stimulate phosphorylation of FOXO1. The cellular abundance and consequently activity of FOXO1 are halved in T2D. Interestingly, inhibition of mTORC1 with rapamycin reduces the abundance of FOXO1 to the levels in T2D. This suggests that the reduction of the concentration of FOXO1 is a consequence of attenuation of mTORC1, which defines much of the diabetic state in human adipocytes. We integrate insulin control of FOXO1 in a network-wide mathematical model of insulin signaling dynamics based on compatible data from human adipocytes. The diabetic state is network-wide explained by attenuation of an mTORC1-to-insulin receptor substrate-1 (IRS1) feedback and reduced abundances of insulin receptor, GLUT4, AS160, ribosomal protein S6, and FOXO1. The model demonstrates that attenuation of the mTORC1-to-IRS1 feedback is a major mechanism of insulin resistance in the diabetic state.

Indexed as

Models, BiologicalSignal TransductionAdipocytesCells, CulturedDiabetes Mellitus, Type 2FemaleForkhead Box Protein O1Glucose Transporter Type 4GTPase-Activating ProteinsHumansInsulinInsulin Receptor Substrate ProteinsMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesPhosphorylationTOR Serine-Threonine KinasesForkhead Box Protein O1FOXO1 protein, humanGlucose Transporter Type 4GTPase-Activating ProteinsInsulinInsulin Receptor Substrate ProteinsIRS1 protein, humanMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesSLC2A4 protein, humanTBC1D4 protein, humanTOR Serine-Threonine Kinasesadipocytehumaninsulin resistanceinsulin signalingmammalian target of rapamycin (mTOR)mathematical modelingprotein phosphorylationribosome biogenesistranscription factortype 2 diabetes

Identifiers

PMID27226562
PMCPMC4957062
OpenAlexW2502719767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.